Wild type kit inhibitors

A method of treating a subject suffering from a disease or disorder, comprising administrating to the subject an effective amount of a compound having the structure of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• Ring A is selected from tetrazole or triazole, wherein said tetrazole or triazole is optionally substituted with Ra;
• wherein Ra is selected from hydrogen, C1-6 alkyl, C1-6haloalkyl, C0-5alkylphenyl, C0-5alkylC3-6cycloalkyl, C0-5alkylC6-10spirocycloalkyl, C0-5alkylC5-10bridgedbicycloalkyl, C0-5alkyl(4-6 membered heterocycle), C0-5alkyl(7-10 membered spiroheterocycle), and C0-5alkyl(5-10 membered bridgedbicycloheterocycle), wherein said heterocycle,
• spiroheterocycle, and bridged bicylcoheterocycle contain at least one N or O, and said alkyl, haloalkyl, phenyl, cycloalkyl, spirocycloalkyl, bridgedbicycloalkyl, heterocycle, spiroheterocycle, or bridgedbicycloheterocycle is optionally substituted with 1-5 Rb, wherein:
• each Rb is independently selected from OH, CN, C1-6alkoxy, C1-6haloalkoxy, C3-5cycloalkoxy, SO2C1-4alkyl, SO2C1-4haloalkyl, C(O)OC1-4alkyl, SO2(C0-2alkyl)(4-6 membered heterocycle containing at least one O or N), SO2(C1-4alkyl)C1-4haloalkoxy, SO2(C1-4alkyl)C1-4alkoxy(C0-1alkoxy), SO2(C1-4alkyl)OH, SO2(C0-2alkyl)C3-6cycloalkyl, C1-3alkyl, C1-5haloalkyl, halogen, and C1-2alkylOH, further wherein said cycloalkyl is optionally substituted with C1-3alkyl;
• each R1 is independently selected from halogen, C1-6alkyl, C1-6haloalkyl, C3-6cycloalkyl, C0-4alkylOH, C6-10spirocycloalkyl, C0-6alkylC1-6alkoxy, C0-4alkylC1-6haloalkoxy, NH2, NHC1-6alkyl, N(C1-6alkyl)2, NH-(4-6 membered heterocycle or 5-6 membered heteroaryl containing at least one O or N), 4-6 membered heterocycle, 7-10 membered fused bicycloheterocycle, 7-10 membered spiroheterocycle, and 5-6 membered heteroaryl containing at least two N, wherein said heterocycle, fused bicycloheterocycle, and spiroheterocycle contain at least one N or O, and said alkyl, haloalkyl, alkoxy, cycloalkyl, spirocycloalkyl, heterocycle, or heteroaryl is optionally substituted with 1-3 Re;
• each Re is independently selected from deuterium, deuterated C1-4alkyl, deuterated C1-4alkoxy, C1-4haloalkoxy, halogen, C0-3alkyl-S(O)2C1-3alkyl, C0-3alkyl-S(O)(NH)C1-3alkyl, (C1-4alkyl)P(O)(C1-3alkyl)2, C1-4alkyl, CN, CHF2, C3-6cycloalkyl, C1-4haloalkyl, C0-4alkylOH, C1-4alkyl(OH)(C1-C4alkoxy), C0-4alkylC1-4alkoxy, C1-3alkoxyC1-3alkoxy, NH2, NH(C1-6alkyl), N(C1-6alkyl)2, and (C0-4alkyl)-(4-6 membered heterocycle containing at least one O or N),
• wherein said heterocycle is optionally substituted with 1-3 C0-3alkylOH;
• each R9 is independently selected from C1-3alkyl, C1-3haloalkyl, halogen, CN, and C3-4cycloalkyl;
• n is 1 or 2;
• and
• p is 0, 1 or 2;
• wherein the disease or disorder is selected from urticaria, atopic dermatosis, allergic asthma, prurigo nodularis, allergic conjunctivitis, allergic rhinitis, amyotrophic lateral sclerosis (AML), chronic rhinosinusitis with nasal polyps, irritable bowel syndrome (IBS), food allergies, eosinophilic esophagitis and mast cell activation syndrome (MCAS).